Jessica Waninger

Mrs. Jessica Waninger

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Cancer Cell
Verified
Journal Article
Closed access
ACAndrew Chow
Andrew Chow
SSSara Schad
Sara Schad
MGMichael Green
Michael Green
MHMatthew D. Hellmann
Matthew D. Hellmann
VAViola Allaj
Viola Allaj
TMTaha Merghoub
Taha Merghoub

20 December 2021 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
JWJessica Waninger
Jessica Waninger
TBTyler S. Beyett
Tyler S. Beyett
VGVarun V. Gadkari
Varun V. Gadkari
RSRonald F. Siebenaler
Ronald F. Siebenaler
CKCarson Kenum
Carson Kenum
JTJohn Tesmer
John Tesmer
Oncogenic mutations in KRAS result in a constitutively active, GTP-bound form that in turn activates many proliferative pathways. However, because of its compact and simple architecture, directly targeting KRAS with small molecule drugs has been challenging. Another approach is to identify targetable proteins that interact with KRAS. Argonaute 2 (AGO2) was recently identified as a protein that facilitates RAS-driven oncogenesis. Whereas previous studies described the in vivo effect of AGO2 on cancer progression in cells harboring mutated KRAS, here we sought to examine their direct interaction using purified proteins. We show that full length AGO2 co-immunoprecipitates with KRAS using purified components, however, a complex between FL AGO2 and KRAS could not be isolated. We also generated a smaller N-terminal fragment of AGO2 (NtAGO2) which is believed to represent the primary binding site of KRAS. A complex with NtAGO2 could be detected via ion-mobility mass spectrometry and size exclusion chromatography. However, the data suggest that the interaction of KRAS with purified AGO2 (NtAGO2 or FL AGO2) is weak and likely requires additional cellular components or proteo-forms of AGO2 that are not readily available in our purified assay systems. Future studies are needed to determine what conformation or modifications of AGO2 are necessary to enrich KRAS association and regulate its activities.

24 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JWJessica Waninger
Jessica Waninger
LFLeslie A. Fecher
Leslie A. Fecher
CLChristopher Lao
Christopher Lao
SYSarah Yentz
Sarah Yentz
MGMichael Green
Michael Green
HDHakan Demirci
Hakan Demirci
Background: There is no standardized treatment for metastatic uveal melanoma (MUM) but immune checkpoint inhibitors (ICI) are increasingly used. While ICI has transformed the survival of metastatic cutaneous melanoma, MUM patients do not equally benefit. Factors known to affect ICI response include the hematologic markers, lactate dehydrogenase (LDH) and neutrophil:lymphocyte ratio (NLR). We evaluated the prognostic value of LDH and NLR at the start of ICI and on treatment in MUM. Methods: MUM patients were treated between August 2006 and May 2022 with combination ipilimumab/nivolumab or ipilimumab/nivolumab/pembrolizumab single-agent therapy. Univariable (UVA) and multivariable (MVA) analyses were used to assess the prognostic value of predefined baseline factors on progression-free (PFS) and overall survival (OS). Results: In forty-six patients with MUM treated with ICI, elevated baseline and on-treatment LDH was prognostic for OS (start of ICI, HR (95% CI): 3.6 (1.9–7.0), p < 0.01; on-treatment, HR (95% CI): 3.7 (1.6–8.8), p < 0.01) and PFS (start of ICI, (HR (95% CI): 2.8 (1.5–5.4), p < 0.0001); on-treatment LDH (HR (95% CI): 2.2 (1.1–4.3), p < 0.01). On-treatment NLR was prognostic for PFS (HR (95% CI): 1.9 (1.0–3.9), p < 0.01). On-treatment LDH remained an important contributor to survival on MVA (OS: HR (95% CI): 1.001 (1.00–1.002), p < 0.05); PFS: HR (95% CI): 1.001 (1.00–1.002), p < 0.01). Conclusions: This study demonstrates that LDH and NLR could be useful in the prognostication of MUM patients treated with ICI. Additional studies are needed to confirm the importance of these and other prognostic biomarkers.

4 September 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
APAshley N. Pearson
Ashley N. Pearson
JWJessica Waninger
Jessica Waninger
AHAmanda K. Huber
Amanda K. Huber
EHErin A. Holcomb
Erin A. Holcomb
JJJadyn G. James
Jadyn G. James
MGMichael Green
Michael Green
Liver metastases are associated with poor cancer outcomes in many solid malignancies, but the factors influencing the trajectory of patients with liver metastases are poorly defined. It is known that liver metastases suppress systemic antitumor immunity; however, the underlying mechanisms remain incompletely described. We report that liver metastases promote disease progression in patients and preclinical models. Patients with liver metastases progress rapidly, regardless of primary tumor type. In multiple murine models, we find that liver metastases potentiate neutrophil migration and activity. Neutrophils licensed by liver metastasis augment metastatic colonization in an IL1-dependent manner. Thus, liver metastasis rewires systemic immunity to promote cancer progression. This work has implications for treatment strategies to address the poor clinical outcomes associated with liver metastasis.

2 October 2024 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
JWJessica Waninger
Jessica Waninger
FDF. Yesim Demirci
F. Yesim Demirci
HDHakan Demirci
Hakan Demirci

2 December 2025
Verified
Other
Open access
APAshley N. Pearson
Ashley N. Pearson
JWJessica Waninger
Jessica Waninger
AHAmanda K. Huber
Amanda K. Huber
EHErin A. Holcomb
Erin A. Holcomb
JJJadyn G. James
Jadyn G. James
MGMichael Green
Michael Green
Liver metastases are associated with poor cancer outcomes in many solid malignancies, but the factors influencing the trajectory of patients with liver metastases are poorly defined. It is known that liver metastases suppress systemic antitumor immunity; however, the underlying mechanisms remain incompletely described. We report that liver metastases promote disease progression in patients and preclinical models. Patients with liver metastases progress rapidly, regardless of primary tumor type. In multiple murine models, we find that liver metastases potentiate neutrophil migration and activity. Neutrophils licensed by liver metastasis augment metastatic colonization in an IL1-dependent manner. Thus, liver metastasis rewires systemic immunity to promote cancer progression. This work has implications for treatment strategies to address the poor clinical outcomes associated with liver metastasis.